Described as the first unicorn [a startup company valued at over USD 1 billion] of Hong Kong, Cirina has recently merged with Grail to further improve detection of cancer at its early stage. Pharmaboardroom sat down with Professor Denis Lo, the man behind Cirina’s technology, to further discuss his groundbreaking scientific research and achievements in the field of non-invasive blood-based diagnoses.
To start with, what was the rationale behind the recent merger between Cirina and Grail?
"Cirina and Grail have pretty much the same goals. We aim to detect cancer at a stage where it is still possible to do something"
